136 related articles for article (PubMed ID: 18175263)
1. Tandutinib, an oral, small-molecule inhibitor of FLT3 for the treatment of AML and other cancer indications.
Cheng Y; Paz K
IDrugs; 2008 Jan; 11(1):46-56. PubMed ID: 18175263
[TBL] [Abstract][Full Text] [Related]
2. Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics.
DeAngelo DJ; Stone RM; Heaney ML; Nimer SD; Paquette RL; Klisovic RB; Caligiuri MA; Cooper MR; Lecerf JM; Karol MD; Sheng S; Holford N; Curtin PT; Druker BJ; Heinrich MC
Blood; 2006 Dec; 108(12):3674-81. PubMed ID: 16902153
[TBL] [Abstract][Full Text] [Related]
3. Can FLT3 inhibitors overcome resistance in AML?
Tam WF; Gary Gilliland D
Best Pract Res Clin Haematol; 2008 Mar; 21(1):13-20. PubMed ID: 18342808
[TBL] [Abstract][Full Text] [Related]
4. The FLT3 inhibitor tandutinib (formerly MLN518) has sequence-independent synergistic effects with cytarabine and daunorubicin.
Schittenhelm MM; Kampa KM; Yee KW; Heinrich MC
Cell Cycle; 2009 Aug; 8(16):2621-30. PubMed ID: 19625780
[TBL] [Abstract][Full Text] [Related]
5. FLT3 inhibitors for the treatment of acute myeloid leukemia.
Wiernik PH
Clin Adv Hematol Oncol; 2010 Jun; 8(6):429-36, 444. PubMed ID: 20733555
[TBL] [Abstract][Full Text] [Related]
6. FLT3 inhibitors in acute myeloid leukemia.
el-Shami K; Stone RM; Smith BD
Expert Rev Hematol; 2008 Dec; 1(2):153-60. PubMed ID: 21082920
[TBL] [Abstract][Full Text] [Related]
7. Lestaurtinib, a multitargeted tyrosine kinase inhibitor: from bench to bedside.
Shabbir M; Stuart R
Expert Opin Investig Drugs; 2010 Mar; 19(3):427-36. PubMed ID: 20141349
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis, and evaluation of a novel dual FMS-like tyrosine kinase 3/stem cell factor receptor (FLT3/c-KIT) inhibitor for the treatment of acute myelogenous leukemia.
Davies RJ; Pierce AC; Forster C; Grey R; Xu J; Arnost M; Choquette D; Galullo V; Tian SK; Henkel G; Chen G; Heidary DK; Ma J; Stuver-Moody C; Namchuk M
J Med Chem; 2011 Oct; 54(20):7184-92. PubMed ID: 21970471
[TBL] [Abstract][Full Text] [Related]
9. Monitoring of FLT3 phosphorylation status and its response to drugs by flow cytometry in AML blast cells.
Grafone T; Palmisano M; Nicci C; Martelli AM; Emanuela O; Storti S; Baccarani M; Martinelli G
Hematol Oncol; 2008 Sep; 26(3):159-66. PubMed ID: 18383555
[TBL] [Abstract][Full Text] [Related]
10. Investigational drugs targeting FLT3 for leukemia.
Ustun C; DeRemer DL; Jillella AP; Bhalla KN
Expert Opin Investig Drugs; 2009 Oct; 18(10):1445-56. PubMed ID: 19671038
[TBL] [Abstract][Full Text] [Related]
11. Additive effect of PTK787/ZK 222584, a potent inhibitor of VEGFR phosphorylation, with Idarubicin in the treatment of acute myeloid leukemia.
Barbarroja N; Torres LA; Luque MJ; Carretero RM; Valverde-Estepa A; Lopez-Sanchez LM; Rodriguez-Ariza A; Velasco F; Torres A; López-Pedrera C
Exp Hematol; 2009 Jun; 37(6):679-91. PubMed ID: 19463770
[TBL] [Abstract][Full Text] [Related]
12. FLT3 inhibition in acute myeloid leukaemia.
Knapper S
Br J Haematol; 2007 Sep; 138(6):687-99. PubMed ID: 17655729
[TBL] [Abstract][Full Text] [Related]
13. KIT and FLT3 receptor tyrosine kinase mutations in acute myeloid leukemia with favorable cytogenetics: two novel mutations and selective occurrence in leukemia subtypes and age groups.
Sritana N; Auewarakul CU
Exp Mol Pathol; 2008 Dec; 85(3):227-31. PubMed ID: 18977345
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML.
Walker AR; Komrokji RS; Ifthikharuddin J; Messina P; Mulford D; Becker M; Friedberg J; Oliva J; Phillips G; Liesveld JL; Abboud C
Leuk Res; 2008 Dec; 32(12):1830-6. PubMed ID: 18571721
[TBL] [Abstract][Full Text] [Related]
15. FLT3 internal tandem duplication during myelodysplastic syndrome follow-up: a marker of transformation to acute myeloid leukemia.
Pinheiro RF; de Sá Moreira E; Silva MR; Alberto FL; Chauffaille Mde L
Cancer Genet Cytogenet; 2008 Jun; 183(2):89-93. PubMed ID: 18503825
[TBL] [Abstract][Full Text] [Related]
16. Lestaurtinib: a multi-targeted FLT3 inhibitor.
Fathi AT; Levis M
Expert Rev Hematol; 2009 Feb; 2(1):17-26. PubMed ID: 21082990
[TBL] [Abstract][Full Text] [Related]
17. Discovery of the novel potent and selective FLT3 inhibitor 1-{5-[7-(3- morpholinopropoxy)quinazolin-4-ylthio]-[1,3,4]thiadiazol-2-yl}-3-p-tolylurea and its anti-acute myeloid leukemia (AML) activities in vitro and in vivo.
Li WW; Wang XY; Zheng RL; Yan HX; Cao ZX; Zhong L; Wang ZR; Ji P; Yang LL; Wang LJ; Xu Y; Liu JJ; Yang J; Zhang CH; Ma S; Feng S; Sun QZ; Wei YQ; Yang SY
J Med Chem; 2012 Apr; 55(8):3852-66. PubMed ID: 22452518
[TBL] [Abstract][Full Text] [Related]
18. PKC 412 FLT3 inhibitor therapy in AML: results of a phase II trial.
Stone RM; De Angelo J; Galinsky I; Estey E; Klimek V; Grandin W; Lebwohl D; Yap A; Cohen P; Fox E; Neuberg D; Clark J; Gilliland DG; Griffin JD
Ann Hematol; 2004; 83 Suppl 1():S89-90. PubMed ID: 15124689
[No Abstract] [Full Text] [Related]
19. Heat shock protein 90 inhibition is cytotoxic to primary AML cells expressing mutant FLT3 and results in altered downstream signalling.
Al Shaer L; Walsby E; Gilkes A; Tonks A; Walsh V; Mills K; Burnett A; Rowntree C
Br J Haematol; 2008 May; 141(4):483-93. PubMed ID: 18373709
[TBL] [Abstract][Full Text] [Related]
20. Sorafenib (Nexavar) induces molecular remission and regression of extramedullary disease in a patient with FLT3-ITD+ acute myeloid leukemia.
Safaian NN; Czibere A; Bruns I; Fenk R; Reinecke P; Dienst A; Haas R; Kobbe G
Leuk Res; 2009 Feb; 33(2):348-50. PubMed ID: 18573526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
